The treatment period consisted of 12 monthly visits, the first of which was used to gather the baseline data for the efficacy and safety parameters and also included the first distribution of test and placebo treatments. Subjects who received study drug for more than 6 months were evaluated for safety and efficacy the first 6 months and then for safety only thereafter.